Analyse to win in cold season
This article was originally published in OTC Bulletin & The Rose Sheet
“There is no definitive answer to when and where the cold and flu season will hit, but integrating predictive analytics into the planning process allows OTC companies to be more proactive in anticipating product demand and refining their strategies,” according to Vincent Bartkowiak, IQVIA’s global director of marketing for Consumer Health.
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.